Introduction to Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market :
Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic disorder that primarily affects the lungs and liver. It is characterized by a deficiency in the alpha-1 antitrypsin protein, which plays a crucial role in protecting the lungs from damage caused by enzymes like neutrophil elastase. Without sufficient alpha-1 antitrypsin, individuals with AATD are at a heightened risk of developing lung diseases, particularly chronic obstructive pulmonary disease (COPD), and liver conditions.
The global alpha-1 antitrypsin deficiency augmentation therapy market size is expected to be worth around USD 2517 Mn by 2032 from USD 1,413 Mn in 2022, growing at a CAGR of 6.1% during the forecast period from 2022 to 2032.
For insights on global, regional, and country-level parameters with growth opportunities from 2023 to 2032 – Please check this report:https://market.us/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-market
Fastest Growing Market:
- Increasing Prevalence and Awareness:
- Rising awareness about Alpha-1 Antitrypsin Deficiency (AATD) is leading to more diagnoses, thereby increasing the demand for augmentation therapy.
- The prevalence of AATD is on the rise due to improved genetic testing and screening methods.
- Growing Patient Pool:
- The expanding population of AATD patients, especially in regions with a higher genetic predisposition, is a driving factor for market growth.
- Early diagnosis and treatment initiation are becoming more common, further boosting the patient pool.
Market Regional Analysis:
-North America [United States, Canada, Mexico]
-South America [Brazil, Argentina, Columbia, Chile, Peru]
-Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
-Middle East Africa [GCC, North Africa, South Africa]
-Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
Market Key Players:
- Grifols, S.A. (Spain)
- Kamada Pharmaceuticals
- CSL Limited
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries ltd.
- GlaxoSmithKline PLC
- Arrowhead Pharmaceutical, Inc.
- LFB Biomedicaments S.A.
- Mereo BioPharma Group plc
- Intellia Therapeutics, Inc.
- Inhibrx, Inc.
- Centessa Pharmaceuticals (Z factor)
- Krystal Biotech
- Beam Therapeutics
- LOGICBIO THERAPEUTICS, INC.
- Apic Bio
- Pfizer Inc.
- Other Key Players
Market Top Segmentations:
Based on Product Type
- Prolastin C
- Aralast NP
- Glassia
- Zemaira/Respreeza
Based on End-User
- Hospitals
- Specialty Clinics
- Pharmacies
Make an inquiry before picking up this report @https://market.us/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-market#inquiry
Challenges and Opportunities:
Challenges:
- High Treatment Costs:
- Challenge: Augmentation therapy can be expensive, posing affordability issues for some patients and healthcare systems.
- Lifelong Therapy Requirement:
- Challenge: AATD patients typically require lifelong therapy, which can be logistically and financially burdensome.
Opportunities:
- Rising AATD Prevalence:
- Opportunity: The increasing prevalence of AATD due to improved diagnosis creates a larger patient pool for augmentation therapy.
- Innovations in Therapy:
- Opportunity: Ongoing research and development efforts offer opportunities to create more effective and convenient augmentation therapies.
Contact:
Global Business Development Team – Market.us
Market.us (Powered by Prudour Pvt. Ltd.)
Send Email: inquiry@market.us
Address: 420 Lexington Avenue, Suite 300 New York City, NY 10170, United States
Tel: +1 718 618 4351
Website: https://market.us
